Answers are grounded in this paper and cite their sources.
Lipodystrophies have long been regarded as rare, mostly genetic disorders of metabolism. However, HIV-associated lipodystrophy has emerged as a serious complication of highly active antiretroviral therapy. Peroxisome proliferator-activated receptor (PPAR)-ã is now known to be an important transcrip ion factor involved in adipocyte differentiation and function. Consequently, PPARã has emerged as an important pathophysiological mechanism in one of the hereditary lipodystrophies (familial partial lipodystrophy type 3) and in HIV-associated lipodystrophy. Furthermore, the potential of PPARã agonists in lipodystrophies is under active investigation.
No takes yet. Share an insight, caveat, or question.
Tamsma et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: